US 2017/0304343 A1 · BINDING PROTEINS SPECIFIC FOR LOX1 AND USES THEREOF

Abstract

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.

Claims28

Dependent claims

(canceled)

An isolated LOX1-binding protein comprising a set of complementary determining regions (CDRs):

heavy chain variable region (VH)-CDR1, VH-CDR2, VH-CDR3, and light chain variable region (VL)-CDR1, VL-CDR2 and VL-CDR3, wherein:
(a) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:2;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:3;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:30;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:31;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:32;
(b) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:5;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:14;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:30;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:31;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:32;
(c) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:38;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:39;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:44;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:55;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:60;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:61;
or
(d) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:38;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:39;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:40;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:55;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:56;
and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:57.

27 more elements

Dependencies are inferred from the claim text.

Binding proteins specific for lox1 and uses thereof

Life of this patent

Binding proteins specific for lox1 and uses thereof

Life of this patent

Abstract

Claims28